ChemoCentryx Stock News

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ: CCXI ) following the Q4 results. Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter. Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike is positive. In contrast, management''s January 2022 commentary was perceived as cautious/negative by … Full story available on Benzinga.com

ChemoCentryx Inc (NASDAQ: CCXI ) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results. ChemoCentryx reported quarterly losses of 58 cents per share which missed the analyst consensus estimate of a loss of 50 cents per share. ChemoCentryx also reported quarterly sales of $2.31 million which missed the analyst consensus estimate of $11.62 million by 80%. … Full story available on Benzinga.com

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results. ChemoCentryx reported

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2021 Results - Earnings Call Transcript

ChemoCentryx press release (CCXI): Q4 GAAP EPS of -$0.58 in-line.Revenue of $2.32M (-46.8% Y/Y) misses by $1.58M.Shares -14.6%.

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering $45 million milestone from Vifor Pharma received in Q1 2022 --

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -1.75% and 33.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (NASDAQ:CCXI) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.55 (-27.9% Y/Y) and the consensus…

An investigation on behalf of current long term investors in ChemoCentryx, Inc. (NASDAQ:CCXI) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc. Investors who are current long term investors in ChemoCentryx, Inc. (NASDAQ: CCXI) shares, have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: CCXI stocks follows a lawsuit filed against ChemoCentryx, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CCXI stocks, concerns whether certain ChemoCentryx, Inc. directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that the plaintiff claims that between November 26, 2019 and May 3, 2021, the defendants made false and/or misleading statements and/or failed to disclose that the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis, that the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan, that these issues presented a substantial concern regarding the viability of ChemoCentryx''s NDA for avacopan for the treatment of ANCA-associated vasculitis, and that as a result of the foregoing, Defendants'' public statements were materially false and misleading at all relevant times.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company''s fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released aft

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time.

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir